Gastric cancer risk and pathogenesis in brca1 and brca2 carriers

HIGHLIGHTS

  • who: Kole H. Buckley and collaborators from the Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Civic Center Blvd, Philadelphia, PA, USA have published the research work: Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers, in the Journal: Cancers 2022, 5953 of 15/Nov/2022
  • what: While the studies suggest improved responsiveness of BRCA1/2associated GCs to platinum-based intervention, other DNA damaging agents such as PARP inhibitors (PARPi) may also prove useful as PARPi have shown selective killing of BRCA1/2 mutant tumor cells .
  • future: Given . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?